keyang zhu

Dr. keyang zhu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
LZLing Zhang
Ling Zhang
QLQian Liu
Qian Liu
HHHaoran Hu
Haoran Hu
LZLu Zhao
Lu Zhao
KZkeyang zhu
keyang zhu
Mesenchymal stem cells (MSCs) have therapeutic value in many diseases. Mitochondria transfer can promote wound healing and can potentially be applied to the repair of damaged tissue, but the specific mechanisms and regulatory factors involved remain unclear. In this review, we discuss the mechanistic basis of mitochondria transfer and factors that restore mitochondrial function in injured somatic cells.

6 November 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
YRYanqian Ruan
Yanqian Ruan
LZLing Zhang
Ling Zhang
LZLina Zhang
Lina Zhang
KZkeyang zhu
keyang zhu

12 August 2025 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Open access
LLLan Li
Lan Li
ZLZheting Liu
Zheting Liu
HHHaoran Hu
Haoran Hu
QWQiuru Wang
Qiuru Wang
JWJing Wang
Jing Wang
LZLing Zhang
Ling Zhang
Diabetic cardiomyopathy (DCM), a major cause of diabetic mortality, lacks effective therapies. This study investigated the cardioprotective role of Heterophyllin B (HET-B), a natural compound and its underlying mechanisms in DCM. Using streptozotocin-induced DCM mice and high glucose (HG)-treated H9C2/neonatal cardiomyocytes, we assessed cardiac function, mitochondrial homeostasis, and apoptosis. HET-B significantly improved cardiac function, indicated by increased ejection fraction (EF) and fractional shortening (FS). It also reduced cardiomyocyte apoptosis (in vivo/vitro), and ameliorated HG-induced mitochondrial damage, characterized by dysfunction, fragmentation, and excessive reactive oxygen species (ROS) production. HET-B enhanced mitochondrial fusion protein OPA1 expression and reduced Bax/Bcl2, cytochrome C (Cyt C) release and caspase-3 cleavage. Molecular docking and cellular thermal shift assays identified mitochondrial antiviral-signaling protein (MAVS) as a potential target of HET-B. HET-B reversed MAVS downregulation induced by HG/DCM in vitro and in vivo. Importantly, MAVS knockdown via siRNA abolished HET-B's protection against HG-induced apoptosis and mitochondrial damage. Furthermore, HET-B restored HG-impaired autophagic flux, reducing autolysosome accumulation and normalizing LC3-II. Collectively, the natural compound HET-B alleviates diabetic myocardial injury by targeting MAVS to enhance autophagy, maintain mitochondrial homeostasis, and inhibit cardiomyocyte apoptosis, positioning it as a promising therapeutic candidate for DCM.

10 August 2026 in Diabetologia
Verified
Journal Article
Closed access
PDF file
ZLZheting Liu
Zheting Liu
HYHoufa Yin
Houfa Yin
KZkeyang zhu
keyang zhu
SLShan Li
Shan Li
YWYiqiong Wang
Yiqiong Wang
LZLing Zhang
Ling Zhang